Related Experiment Video
Updated: Apr 11, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Drug-eluting balloons to treat iliac in-stent restenosis
Nicola Troisi1, Leonardo Ercolini1, Elisa Peretti2
1Department of Surgery, Vascular and Endovascular Surgery Unit, San Giovanni di Dio Hospital, Florence, Italy.
Insights
Drug-eluting balloons (DEBs) offer a safe and effective treatment for iliac in-stent restenosis (ISR). This study shows promising early and two-year outcomes for DEB use in patients with iliac ISR.
Area of Science:
- Vascular Surgery
- Interventional Cardiology
- Medical Devices
Background:
- Iliac in-stent restenosis (ISR) presents a clinical challenge.
- Drug-eluting balloons (DEBs) are a potential treatment modality for ISR.
Purpose of the Study:
- To evaluate the safety and efficacy of DEBs for treating symptomatic iliac ISR.
- To report clinical outcomes in patients treated with DEBs for iliac ISR.
Main Methods:
- Retrospective case series of six patients treated with DEBs for iliac ISR.
- Follow-up included assessment of technical success, lesion healing, symptom relief, patency, and limb salvage.
Main Results:
- Technical success was achieved in all six patients.
- 83.3% of patients experienced lesion healing and symptom relief.
- Estimated 2-year rates for overall patency and limb salvage were 100%.
Conclusions:
- DEBs demonstrate safety and effectiveness in treating iliac ISR.
- Promising early and 2-year outcomes support DEB use.
- Further research with larger cohorts is warranted.
Background:
To report our experience in the use of drug-eluting balloons (DEBs) for the treatment of symptomatic iliac in-stent restenosis (ISR).
Case Reports:
Six patients underwent treatment using DEBs for iliac ISRs in our centers between September 2011 and May 2014. The patients were predominantly women (4 of 6, 66.7%) with a mean age of 67.2 years (range, 46-75 years). Technical success was achieved in all cases. During the follow-up (mean duration, 15.5 months; range, 3-30 months), healing of the lesions/relief of symptoms was obtained in 5 of 6 cases (83.3%). Estimated 2-year rates of overall patency and limb salvage were 100%.
Conclusions:
The use of DEBs in the treatment of iliac ISR is safe and effective. The early and 2-year outcomes are promising. However, further experience with larger patient groups is needed.
More Related Videos
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
06:55Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
Published on: October 26, 2016
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...